The median survival of patients with primary amyloidosis without cardiac involvement is about 4 years, but patients with cardiac involvement (AL-CA) and a significant increase in levels of N-terminal precursor of brain natriuretic peptide (NT-proBNP) or cardiac troponin T (TnT) have a poor prognosis, with a median survival of only 8 months [3, 4]. Here, NPPB is linked to axial length measurement.